UCLA Team Reports Positive Topline Results from Double-Blind Trial of NeuroSigma's Non-Invasive eTNS System for Treatment of Pediatric ADHD

Primary and secondary endpoints statistically significant LOS ANGELES, Oct. 30, 2017 -- (Healthcare Sales & Marketing Network) -- NeuroSigma, Inc. (NeuroSigma) today announced that on Friday, October 27, 2017, at the Annual Meeting of the American Acad... Devices, Neurology NeuroSigma, eTNS , Trigeminal Nerve Stimulation, ADHD
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news